Comera Life Sciences Holdings EBIT

The latest EBIT for CMRA is $-9.2M as of September 2023. That compares with $-11M in the prior-year period — up 17.3% year over year. That is above the sector sector average of $-63M. Investors often review this figure alongside Comera Life Sciences Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, CMRA's EBIT moved from $-11M to $-9.2M — a 17.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Comera Life Sciences Holdings's operating scale or balance-sheet position.

Against its sector companies, CMRA currently prints $-9.2M for EBIT, while the sector average sits near $-63M. That is roughly 85.3% above the sector mean. Large gaps often invite a closer look at Comera Life Sciences Holdings's growth, margins, and balance sheet.

A EBIT figure of $-9.2M for CMRA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-63M. Explore the charts below for those layers of context.

After noting CMRA's EBIT ($-9.2M), review year-over-year change from $-11M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.